Posted inCardiology Diabetes & Endocrinology news

SGLT2 Inhibitors Offer Potent Protection Against Contrast-Induced Kidney Injury During Coronary Intervention

No Comments

Highlight

According to data from the BMC2 registry, patients with diabetes who were receiving SGLT2 inhibitors (SGLT2i) prior to percutaneous coronary intervention (PCI) experienced a 28% reduction in the odds of developing contrast-associated acute kidney injury (CA-AKI) compared to non-users.

The protective signal remained robust even after rigorous propensity-score matching and risk adjustment, with the benefits extending to various high-risk patient subgroups, suggesting a broad clinical utility for these agents in the catheterization lab setting.

Tags:
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

No Comments

Highlight

  • SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% (HR 0.62), with benefits consistent across all stages of kidney function.
  • Significant renoprotection was observed even in patients with Stage 4 CKD (eGFR <30 mL/min/1.73 m2) and those with minimal albuminuria (UACR ≤30 mg/g).
  • The therapy slowed the annual rate of eGFR decline and reduced the risk of kidney failure by 34%, independent of diabetes status.
  • Results support the routine use of SGLT2 inhibitors as a foundational therapy for kidney protection across a much broader patient population than previously established.

Background: The Evolution of Renoprotection

Tags:
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

No Comments

Highlights

– Meta-analysis of 10 randomized placebo-controlled trials (SMART‑C; n=70,361) finds SGLT2 inhibitors lower CKD progression by ~38% (HR 0.62) and kidney failure by ~34% (HR 0.66).

– Benefits were consistent across baseline eGFR categories including eGFR <30 mL/min/1.73 m2 (stage 4 CKD) and across UACR ranges including normoalbuminuria (≤30 mg/g).

Tags:

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply